History

In 1996, researchers at Penn State in Hershey, Pennsylvania identified the KISS1 gene as a melanoma metastasis suppressor. In 2001, three groups independently found that its peptide product activates the receptor now called KISS1R. By late 2003, loss-of-function mutations in that receptor were shown to cause failure of puberty in humans. The first human dosing came in 2005 using kisspeptin-54; defining kisspeptin-10 pharmacology studies followed in 2011. In 2024, WADA banned kisspeptin and an FDA advisory committee declined to allow it in pharmacy compounding.

Kisspeptin-10 sits in an unusual spot. It is a real, well-characterized hormone fragment with genuine human pharmacology data behind it, not a hypothetical molecule dreamed up for a supplement label. Inject it and, in the right people at the right time, reproductive hormones reliably go up. That much is established. But the impressive clinical results people cite when they sell kisspeptin online, zero-risk IVF triggering and improved sexual desire, came from a different, longer-lasting molecule called kisspeptin-54. For Kisspeptin-10 itself, the human evidence is small, short, and limited to hormone measurements rather than real-world outcomes. This profile keeps those two molecules carefully separate.

What it is

Kisspeptin-10 (Kp-10) is a decapeptide: ten amino acids in the sequence Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe, capped with an amide group. It is the conserved C-terminal core shared by the larger kisspeptin family members (kisspeptin-54, -14, -13 and -10), corresponding to residues 45–54 of kisspeptin-54. It belongs to the RFamide peptide family, and that terminal arginine-phenylalanine-amide is essential for activating its receptor. Structural work shows the molecule forms a short helical region toward its C-terminal end; alanine-scanning studies found that substituting position 6 blunts the response while substituting position 10 abolishes it entirely and disrupts that helix.

Mechanistically, Kp-10 binds KISS1R (the receptor formerly called GPR54), a G-protein-coupled receptor sitting on GnRH neurons in the hypothalamus. Activation depolarizes those neurons and triggers pulsatile release of GnRH, which in turn drives the pituitary to release luteinizing hormone (LH, most strongly) and follicle-stimulating hormone (FSH), which then prompt the gonads to make sex steroids such as testosterone. Kisspeptin signaling is now understood to be a master upstream gatekeeper of puberty and adult reproduction; without it, the whole axis fails to start.

A naming caution: “metastin” and “kisspeptin-54” refer to the larger 54-amino-acid peptide, not to Kp-10. They are related but not interchangeable, and the distinction matters for reading the evidence.

The claims

In legitimate research, Kp-10 is used as an acute stimulation test for the reproductive hormone axis and as a tool to study how GnRH pulses are generated, how puberty begins, and what goes wrong in conditions like hypogonadism and hypothalamic amenorrhea.

The more ambitious clinical-development goals, an IVF egg-maturation trigger that avoids ovarian hyperstimulation syndrome, treatments for hypothalamic amenorrhea, diagnostic axis testing, and therapy for low sexual desire, have mostly been pursued with kisspeptin-54, not Kp-10.

Gray-market marketing then layers on consumer claims that outrun the Kp-10-specific data entirely: boosting testosterone or libido, serving as a “natural” alternative to testosterone replacement or to clomiphene/enclomiphene, enhancing fertility, or restarting the hormone axis after anabolic steroid use. None of these consumer-facing promises rest on outcome trials of Kisspeptin-10.

The evidence

The honest summary is that Kp-10 does what its mechanism predicts in short human experiments, and nothing more has been proven.

Human data on Kisspeptin-10 specifically. George and colleagues (Journal of Clinical Endocrinology & Metabolism, 2011) gave intravenous Kp-10 to healthy men as both boluses and continuous infusion. Continuous infusion raised mean LH, LH pulse frequency, LH pulse size, and testosterone, and was well tolerated with no significant adverse events. The effect is real, but the sample was tiny and the exposure acute. Jayasena and colleagues (also JCEM, 2011) showed the response is sexually dimorphic: Kp-10 raised LH and FSH in men even at low doses, did not raise gonadotropins in women during the follicular phase of the cycle even at high doses, but did raise them in women during the preovulatory phase. So the effect depends on sex and on cycle timing.

The kisspeptin-54 context, which is not Kp-10 evidence. The landmark first-in-human study (Dhillo et al., JCEM 2005) that raised LH, FSH and testosterone in men used kisspeptin-54, as its title states. The promising IVF work, an open-label Phase 2 trial in 60 women at high risk of ovarian hyperstimulation (Abbara et al., JCEM 2015) and a follow-up randomized second-dose trial in 62 women (Abbara et al., Human Reproduction 2017), used kisspeptin-54. So did the two crossover randomized trials in low sexual desire published in JAMA Network Open (32 premenopausal women in 2022; 32 men in 2023, where penile tumescence rose up to 56% over placebo). These are interesting results, but attributing them to Kisspeptin-10 is simply incorrect.

Animal data. Across many species, kisspeptin (including Kp-10) drives GnRH and LH release, and loss of the gene or receptor causes failure of puberty and hypogonadotropic hypogonadism. The mechanism is well established preclinically.

What is missing, and the skeptical read. There are no clinical-outcome randomized trials for Kp-10 itself; every Kp-10 human study is acute and biomarker-level. Almost all human kisspeptin trials come from a single group at Imperial College London, so independent replication is sparse. Several trial authors disclosed consulting fees from Myovant Sciences, and one was employed by Invicro; funding came from the UK’s NIHR and Medical Research Council. Pharmacology is the practical limiter: Kp-10’s terminal half-life is roughly four minutes (versus about 28 minutes for kisspeptin-54), and continuous infusion causes receptor desensitization and tachyphylaxis. That is precisely why developers shifted to the longer-acting kisspeptin-54. A 2025 systematic review (Velmurugan et al., Current Medicinal Chemistry) covered 29 interventional trials but framed mostly small, early-phase studies optimistically and made no claim about regulatory approval; it should be read with that caution in mind.

Safety and side effects

In short, controlled research settings, acute infusions of Kp-10 (and of kisspeptin-54) were generally well tolerated, with the trials above reporting no significant adverse events.

The caveats are substantial. There is no long-term human safety data for Kp-10; every trial has been acute, so chronic effects on the hormone axis, bone, mood and cardiovascular system are simply unstudied. Tachyphylaxis with continuous dosing is a known pharmacologic liability. Unsupervised manipulation of the reproductive hormone axis carries theoretical risks of disrupted cycles, unpredictable hormone swings, and interactions with fertility treatments. And because gray-market material is sold as “research chemical, not for human use,” product quality, including purity, sterility and endotoxin content, is an independent hazard with no oversight.

Legal and regulatory status

Kisspeptin-10 is not approved by the FDA, or any other regulator, for any indication; it remains investigational. On October 29, 2024, the FDA’s Pharmacy Compounding Advisory Committee voted against adding kisspeptin-10 to the 503A bulk-drug-substances list (it had been nominated for secondary hypogonadism in men), so compounded Kp-10 is not an FDA-sanctioned bulk substance. No marketing approval for kisspeptin in any form has been identified anywhere internationally.

In sport, kisspeptin is prohibited. It was added as a named example to the 2024 WADA Prohibited List under category S2 (peptide hormones, growth factors, related substances and mimetics) as a testosterone-stimulating peptide, which means it is banned at all times, in and out of competition.

In practice, Kp-10 is sold online as a “research chemical,” with no oversight of its identity, purity or sterility, and with the one formal pathway toward compounded use having been specifically declined.

Bottom line

Kisspeptin-10 is a legitimate research tool with a clear, proven mechanism: it raises reproductive hormones in short human studies, in a way that depends on sex and cycle timing. That is the extent of what has been demonstrated for this specific molecule. There are no trials showing it improves fertility, sexual function, or any other clinical outcome, and its very short half-life and tendency to cause receptor desensitization are why drug developers favored the related kisspeptin-54 instead. The compelling fertility and libido headlines belong to that other molecule and should not be read as evidence for Kp-10. It is unapproved everywhere, declined for compounding, and banned in sport. The honest grade is preliminary human: some real human data, all of it small, acute, and short.

Kisspeptin-10: A Real Hormone Switch With Thin Human Evidence